Manuso stated the same old sh it. But did state that SGI1776 will be announced in the next few days as dosing it's first patient. The first group will be refractory prostate and Lym. patients.
The second group in the ph1 will will concentrate on refractory Leukemia
This is a oral drug.
Mp-529 will file what's called an investigational IND. This will be used to conserve cash. My guess is that a university will conduct the trial on a limited number of patients. This will most likely slow down how fast this drug can get to a ph 2 trial.
S110- is in the process of IND ebabling paperwork.
Mp-470 Ph2 will be aimed at small/non small cell lung cancer and that we would see some results later this year
One last point, I like the additional info about Sgi-1776. Not only will it inhibit Pim. It also resensitizes the chemo agents. I do not recall seeing that anywhere before. It will be interesting to hear about any toxicity issues. More important, that it saves some lives.